Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 3

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

582

HTML

5226

Tables (1-2)

426

Sum=6234

Mar 10, 2011 (publication date) through Nov 23, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Oncol. Mar 10, 2011; 2(3): 150-157
Published online Mar 10, 2011. doi: 10.5306/wjco.v2.i3.150

Table 1 Selected clinical trials on targeted agents for advanced/metastatic thyroid carcinomas

Trial	Phase	Setting	Patients	Targeted agent	DCR
Cooney et al[38]	II	Advanced pretreated disease	18 with ATC	CA4P alone	33%
Cohen et al[46]	II	Advanced pretreated disease	60 (2 with ATC)	Axitinib alone	71%
Ha et al[53]	II	Advanced pretreated disease	11 with ATC	Imatinib alone	75%
Nagaiah et al[54]	II	Advanced pretreated disease	16 with ATC	Sorafenib alone	40%

ATC: Anaplastic thyroid carcinoma; CA4P: Combretastatin A4; DCR: Disease control rate (complete responses + partial responses + stable disease).

Citation: Perri F, Lorenzo GD, Scarpati GDV, Buonerba C. Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. World J Clin Oncol 2011; 2(3): 150-157
URL: https://www.wjgnet.com/2218-4333/full/v2/i3/150.htm
DOI: https://dx.doi.org/10.5306/wjco.v2.i3.150